Filter
2806
Filtered Results: 2806
Text search:
Centers
of
Disease
Control
CDC
Featured
Recommendations
297
New Publications
725
Language
Document type
No document type
1495
Guidelines
438
Studies & Reports
336
Manuals
143
Fact sheets
133
Strategic & Response Plan
103
Training Material
54
Infographics
33
Situation Updates
24
Resource Platforms
23
Brochures
14
Online Courses
6
Dashboards/Maps
2
Videos
2
Countries / Regions
Global
110
Africa
104
Sierra Leone
102
Liberia
93
Nigeria
77
India
75
Ethiopia
73
West and Central Africa
71
Kenya
70
Congo, Democratic Republic of
62
East and Southern Africa
58
Guinea
55
Middle East and North Africa
54
Senegal
50
Uganda
50
Rwanda
47
Ghana
40
Western and Central Europe
40
Tanzania
39
Mozambique
39
Zambia
38
Latin America and the Carribbean
38
South Africa
35
Malawi
35
Haiti
34
Burkina Faso
33
Namibia
33
Côte d’Ivoire / Ivory Coast
29
Guinea-Bissau
28
South Sudan
28
Mali
26
Bangladesh
26
Russia
25
Cameroon
24
Syria
24
Brazil
24
Zimbabwe
22
Cambodia
21
Nepal
20
Germany
20
Yemen
20
USA
19
Colombia
19
Angola
19
Niger
18
Chad
18
Ukraine
18
Madagascar
16
Eastern Europe
14
Philippines
12
Indonesia
12
Asia
12
Botswana
10
Eastern Europe and Central Asia
10
Vietnam
10
Eswatini/ Swaziland
9
Lesotho
9
Myanmar / Burma
8
South–East Asia Region
8
Paraguay
8
Ecuador
7
Pakistan
6
Togo
5
Benin
5
Venezuela
5
France
5
Afghanistan
4
Egypt
4
Thailand
4
Chile
4
Western Pacific Region
4
Laos
4
North America
4
Spain
4
Saudi Arabia
3
Gambia
3
China
3
Sudan
3
Peru
3
Portugal
3
Somalia
2
Lebanon
2
Turkey
2
Central African Republic
2
Argentina
2
Burundi
2
Bolivia
2
Mexico
2
Congo-Brazzaville
2
Timor Leste/ East Timor
2
Gabon
2
Jamaica
2
Mauritius
2
Tunisia
2
Morocco
1
Iraq
1
Malaysia
1
Dominican Republic
1
Honduras
1
Cape Verde
1
Sri Lanka
1
Bhutan
1
Palestine
1
Italy
1
Albania
1
Armenia
1
Southern Africa
1
Tajikistan
1
Qatar
1
Kyrgyzstan
1
Australia
1
Kazakhstan
1
Uruguay
1
Japan
1
Belgium
1
United Kingdom
1
South Korea
1
Morocco
1
Authors & Publishers
Publication Years
Category
Countries
1067
Clinical Guidelines
233
Public Health
144
Key Resources
126
Women & Child Health
81
Pharmacy & Technologies
46
Capacity Building
40
Toolboxes
COVID-19
472
Ebola
232
HIV
217
TB
202
Rapid Response
156
AMR
146
NTDs
79
Zika
76
NCDs
69
Mental Health
65
Caregiver
49
Planetary Health
49
Cholera
41
Refugee
32
Specific Hazards
30
Polio
28
Pharmacy
26
Natural Hazards
25
Disability
19
Global Health Education
18
Conflict
15
Health Financing Toolbox
12
Social Ethics
1
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment ... people infected with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
This report investigates the impact of potential misclassification of samples on HIV prevalence estimates for 23 surveys conducted from 2010-2014. In addition to visual inspection ... laboratory results, we examined how accounting for potential misclassification of HIV status through Bayesian latent class models affected the prevalence estimates. Two types of Bayesian models were specified: a model that only uses the individual dichotomous test results and a continuous model that uses the quantitative information of the EIA (i.e., the signal-to-cutoff values). Overall, we found that adjusted prevalence estimates matched the surveys’ original results, with overlapping uncertainty intervals. This suggested that misclassification of HIV status should not affect the prevalence estimates in most surveys. However, our analyses suggested that two surveys may be problematic. The prevalence could have been overestimated in the Uganda AIDS Indicator Survey 2011 and the Zambia Demographic and Health Survey 2013-14, although the magnitude of overestimation remains difficult to ascertain. Interpreting results from the Uganda survey is difficult because of the lack of internal quality control and potential violation of the multivariate normality assumption of the continuous Bayesian latent class model. In conclusion, despite the limitations of our latent class models, our analyses suggest that prevalence estimates from most of the surveys reviewed are not affected by sample misclassification.
INTRODUCTION: The COVID-19 pandemic has disrupted health systems around the world. The objectives of this study are to estimate the overall effect of the pandemic on essential health service use and...
Guidance Note. The recommended actions are presented under the different components (water supply, hygiene and hand washing, disinfection, solid waste management, latrine and wastewater management, and dead body management) of the defined Ebola Care...
Communicable Disease Control Branch
Communicable Disease Management Protocol – Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome...
Department of AIDS Control
Ministry of Health & Family Welfare
This information leaflet is for general informative purposes only. It can be used in its current form or further modified and adapted by responsible authorities in each country as a country-specific guidance.
A survival guide for clinicans.
3rd edition.
